Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from Eli Lilly

AbbVie vs Eli Lilly: 1 Is Clearly the Better Dividend Stock to Buy and Hold for the Next 10 Years

While one continues reinvesting for growth, the other has rewarded shareholders for 54 years in a row.

Barchart

A New FDA-Approved Oral Weight Loss Pill Requires No Fasting: What Makes Foundayo Different from Other GLP-1 Drugs

FDA approved Foundayo (orforglipron) on April 1, 2026 — the only oral GLP-1 pill for weight loss you can take any time of day without fasting. Average weight loss: 12.4%. Here's the breakdown.

Medical Daily

Wegovy weight-loss pill goes on sale on UK high street and online pharmacies

Thousands of people begin receiving their first deliveries of once-a-day medication made by Novo Nordisk

The Guardian - UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Eli Lilly just placed a $40 million bet on the next injectable boom

The GLP-1 maker’s latest AI investment targets drug discovery and the future of consumer medicine.

Fortune

Medicare will soon cover costs of weight-loss drugs. Here’s what you can expect to pay.

The Independent UK

Six Underrated Stocks Britain's Top Fund Managers Believe Could Deliver Long-Term Growth

Six top fund managers reveal their favourite under-the-radar investments in healthcare, finance, retail, energy, and consumer goods with long-term growth potential despite risks.

International Business Times UK

'He's Such a Fraud': Trump Cakes Bruised Hands in Makeup as Solon Demands Answers Over 'Terminal Illness' Rumours

Donald Trump's bruised hands, visible in new Oval Office photos, have fuelled uneasy questions about his health after he abruptly cancelled a bipartisan housing bill signing.

International Business Times UK

Read news from The Economist, FT, and more,
with one subscription

Did Trump Get Experimental Obesity Drug? Rep Lieu Demands Answers Over FDA's 'Powerful Drug' Given to 'Unidentified 79-Year-Old Man'

Representative Ted Lieu questions the White House about claims that President Trump accessed an experimental obesity drug reserved for the gravely ill, sparking controversy and speculation.

International Business Times UK

What Is Retatrutide? The Experimental Weight Loss Drug Millions Cannot Access, But Has Sparked a White House Meltdown Over Trump's Health

A 79-year-old man's access to the experimental drug Retatrutide through the FDA's Expanded Access programme has sparked controversy, with allegations of political insider influence and White House denials.

International Business Times UK

Trump Linked to Mystery FDA Deal Granting Early Access to Powerful Weight-Loss Drug for Critical Patients

A 79-year-old patient received early access to Eli Lilly's experimental obesity drug retatrutide, sparking political and medical controversy amid speculation about the patient's identity.

International Business Times UK

White House denies Trump is the ‘well-connected’ man who gained compassionate access to obesity drug in April

A White House spokesman said theories that President Trump sought the drug were ‘baseless speculation’

The Independent UK

AI drug discovery firm Insilico Medicine signs deal with Korea’s SK Biopharmaceuticals worth $2.5 billion

“We want to be the SpaceX of the pharmaceutical industry,” Alex Zhavoronkov, co-CEO of Insilico Medicine, tells Fortune.

Fortune

3 Stocks Doing the Heavy Lifting in Healthcare’s Rebound

Led by Eli Lilly’s GLP-1 success, Humana’s expanding margins, and DexCom’s medtech growth, the healthcare sector is staging a major market rebound.

MarketBeat

Trump's unusual stock frenzy: Portfolio shows 3,600 trades in 90 days

Trump's investment accounts saw thousands of trades totaling hundreds of millions of dollars between January and March. This feverish activity, dominated by tech stocks, has drawn scrutiny from lawmakers and ethics experts over potential conflicts of interest, though the Trump Organization denies the president's direct involvement.

The Economic Times

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

Everything you need to know about the new Wegovy pill – and whether you should take it or not

LET’S UNPACK THAT: With massive demand for the GLP-1 tablets as they are approved for use in the UK, Helen Coffey asks experts how they differ from the jab and whether they are the next big step in the weight-loss revolution

The Economic Times

Global drugmakers rush to boost US presence as tariff threat looms

Global drug companies are boosting U.S. production and stockpiling medicines. This is a response to potential tariffs on branded drugs. Companies are investing billions in new plants and expanding existing facilities across America. These moves aim to avoid penalties and ensure supply chains remain robust. Several major pharmaceutical firms have…

Medical Daily

Eli Lilly's $2.75 Billion AI Bet on Anti-Aging Drugs Signals a Major Shift in Pharmaceutical Priorities

Eli Lilly's $2.75B AI deal with Insilico Medicine targets age-related diseases. How AI is transforming longevity drug discovery and what it means for patients.

Fortune

Abridge wants to be the operating system for medicine—and NVIDIA and Eli Lilly are helping build it

The $5.3 billion ambient AI startup is expanding from clinical notes into billing, drug trials, and real-time insurance claims.

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

FDA issues new kidney warning for weight loss pill

Alli was the first over-the-counter weight loss pill approved by the U.S. Food and Drug Administration

Medical Daily

Medicare Is About to Cover Weight-Loss Drugs for the First Time — Here's What the GLP-1 Bridge Program Means for Millions of Americans with Obesity

Medicare's GLP-1 Bridge launches July 1, 2026, offering eligible Part D enrollees Wegovy and Zepbound for $50/month — the first-ever Medicare coverage for obesity-specific GLP-1 drugs.

Axios

Innovation in medicine is having a breakthrough moment

Recent weeks have featured a series of positive developments.

The Economic Times

Eli Lilly says next-gen obesity drug curbs sleep apnea, among other benefits

Eli Lilly presented trial results for its new obesity drug retatrutide. The drug significantly reduced sleep apnea severity and knee osteoarthritis pain in adults with obesity. Patients also experienced substantial weight loss. These findings were shared at an American Diabetes Association conference. Retatrutide targets multiple hormones related to obesity and…

AAP

Phemex Expands TradFi Offering Beyond 70 Assets, Bringing Global Equities to 24/7 Crypto Markets

APIA, Samoa, June 3, 2026 /PRNewswire/ -- Phemex, a user-first crypto exchange, expands its TradFi ecosystem to 73 active assets. It includes the recent addition of several high-performance contracts, ranging from healthcare leaders Eli Lilly (LLY) and Novo Nordisk (NVO) to global semiconductor and technology powerhouses like Samsung (SAMSUNG) and…

MarketBeat

Eli Lilly Wins Back CVS Health, Reverting Novo's Advantage

Eli Lilly and Company just secured a big win as it looks to expand GLP-1 access, mending its partnership with top pharmacy benefit manager CVS Health.

The Economic Times

US stocks today: S&P 500 and Nasdaq hit record closing highs as US and Iran agree to extend ceasefire

The S&P 500 and Nasdaq hit record closing highs as hopes of a US Iran ceasefire extension boosted sentiment. Investors also digested US inflation rising to a three-year high and weaker GDP revision. AI and tech stocks led gains, with Microsoft, Snowflake, Eli Lilly and Marvell among top movers today.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations